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Intra-tumor heterogeneity of cancer cells hampers the design of effective therapies and yet it is poorly repro-
duced in experimental models. A recent report by Eirew at al. provides an in-depth analysis of genetic het-
erogeneity of breast tumor xenografts and shows that changes in clonal diversity might not be stochastic.The theory of evolution is one of the
most important scientific concepts, in
part because it provides a framework to
explain changes in biological systems.
Despite the recognition that tumorigen-
esis follows somatic Darwinian evolution,
our studies and treatment of cancers
have largely ignored evolutionary princi-
ples (Merlo et al., 2006). The successive
clonal evolution model proposed by Peter
Nowell in 1976 is a fairly accurate depic-
tion of how genetic variability and selec-
tion drive the sequential expansion of
progressively more and more malignant
tumor cell populations (Nowell, 1976).
However, this model largely ignores the
relevance of non-genetic variability, minor
clones, and potential functional interac-
tions among clones within tumors. The
alternative cancer stem cell model pro-
posed more recently was built on the
hypothesis that tumors maintain the dif-
ferentiation hierarchy of normal tissues,
thus, only cells with stem or progenitor
cell features contribute to tumor evolution
(Kreso and Dick, 2014). A major defi-
ciency of this model is that it ignores
intra-tumor genetic heterogeneity and
the fact that because tumors have no
biological function, there is no selective
advantage of maintaining differentiated
cell phenotypes. In reality, genetic and
epigenetic heterogeneity, including differ-
entiation state-related epigenetic hetero-
geneity, are both a form of intra-tumor
heterogeneity, and variability for these
features combined with selection is what
drives tumor progression.
Experimental modeling of human tu-
mor evolution has relied on the use of
patient-derived xenografts (PDXs): inject-
ing tumor cells into immunocompromised
mice followed by serial transplantationand subsequent analyses. Some of these
assays are conducted by injecting individ-
ual cancer cells dissociated from their
natural environment, which precludes
the analysis of clonal dynamics. Even
transplanting chunks of tumors or dissoci-
ated mixtures of cancer cells leads to the
outgrowth of tumors that do not fully
reproduce the heterogeneity of the pa-
tient sample due to the significant evolu-
tionary bottleneck imposed by selection
in immunocompromised mice. A recent
study by Eirew et al. (2014) sheds new
light on how intra-tumor clonal heteroge-
neity changes during xenograft growth
by analyzing the genetic composition of
xenografts at the single-cell level.
Advances in genome sequencing tech-
nologies allow the in-depth analysis of
allelic fractions present in a sample to
infer the frequency of cellular subpopula-
tions. The genomic fidelity of PDX models
of breast cancer have been investigated
in several studies by whole-genome
sequencing (Ding et al., 2010; Ellis
et al., 2012). Changes in the frequency
of single nucleotide variants (SNVs) be-
tweenmatched patient tumor and derived
xenograft were attributed mostly to differ-
ences in the fraction of contaminating
normal cells (e.g., fibroblasts and leuko-
cytes), yet it was noted that some clones
that were abundant in xenografts repre-
sented only a minor fraction of cancer
cells in the original patient tumor.
To gain a more in-depth understanding
of how well PDX models reflect the clonal
composition of patient tumors as well as
how clonal dynamics may change during
the serial transplantation of xenografts,
Eirew et al. analyzed the clonality of
15 pairs of primary breast tumors and
derived xenografts serially transplantedCell Stem Cellfor up to 16 passages (Eirew et al.,
2014). Based on whole-genome shotgun
sequencing data, the authors clustered
SNVs to estimate the genotypes of
cellular subpopulations. Comparison of
mutation clusters in xenografts and
parental tumors led to interesting conclu-
sions about changes during initial engraft-
ment and xenograft evolution. In some
cases the engraftment itself posed a
significant selection step because the
dominant clone in the xenograft was
only a minor subpopulation in the original
tumor. A subset of xenografts was poly-
clonal but the clonal structure was distinct
from that of the original tumor. Interest-
ingly, comparison of the initial xenografts
to later passages revealed that tumors
with more significant changes in clonal
composition at first engraftment steps
become less heterogeneous in subse-
quent passages, leading to the domi-
nance of a few clones. In contrast, tumors
with initially moderate alterations in clonal
frequencies displayed more substantial
changes in later passages. This was
observed in both polyclonal and oligoclo-
nal tumors, indicating that the degree of
changes in clonal composition (i.e., clonal
dynamics) does not equal clonal hetero-
geneity per se (Figure 1). The authors
also performed single-cell sequencing of
the tumors, which allowed more detailed
analysis of clonal resolution, and the re-
sults of these corresponded well to bulk
xenograft sequencing data.
Differences in clonal dynamics and
persistence of clones over time in PDX
models have also been observed by
Kreso et al. (2013) who used random len-
tiviral integration sites to monitor the
outgrowth of clones in colorectal cancer
xenografts. In contrast to Eirew’s findings,16, January 8, 2015 ª2015 Elsevier Inc. 11
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Figure 1. Schematic Outline of the Experimental Design and Main Findings by Eirew et al
Transplantation of heterogeneous breast tumors into immunodeficient mice results in xenografts with
different clonal composition. A subset of initial engraftments resulted in polyclonal xenografts, whereas
the majority of cases had reduced clonality (i.e. were oligoclonal). During serial passaging xenografts
with more significant changes in clonal frequencies upon initial passages showed less prominent changes
in subsequent passage, with a few clones dominating the tumors. In contrast, tumors with relatively minor
changes in clonal frequencies at initial engraftment steps displayed more significant alterations at later
passages. Black–gray scale illustrates intensity of clonal dynamics.
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Previewsin this model the xenografts underwent
strong clonal selection upon implantation
but maintained genetic population diver-
sity over serial transplantation. However,
when the clonal identity of the cells was
analyzed based on lentiviral integration
sites, substantial diversity was observed,
suggesting that non-genetic stochastic
variation plays a key role in establishing
and maintaining intra-tumor clonal het-
erogeneity. It is difficult to assess the
underlying reasons for the discrepancy
between these two studies because the
differences might be due to the way clon-
ality was defined, or they might reflect
differences in the biology of breast and
colorectal carcinomas. This is of partic-
ular interest because colon cancer ap-
pears to follow a rather linear tumor evolu-
tion with stepwise genetic changes that
are nearly uniformly observed in all tumors
and include loss of APC as an initiating
event (Fearon and Vogelstein, 1990). In12 Cell Stem Cell 16, January 8, 2015 ª2015contrast, breast cancers display signifi-
cant degrees of intra-tumor heterogeneity
even for known genetic drivers such as
HER2 amplification and mutant PIK3CA.
One of the most interesting findings of
the Eirew study is the surprising repro-
ducibility of the clonal heterogeneity and
dynamics of the xenografts. Transplanta-
tion of the same patient tumor into
different mice at the same time resulted
in the outgrowth of xenografts with very
similar clonal dynamics. This was true
both for tumors that were polyclonal
from the beginning and for the expansion
of clones that were minor subpopulations
in the original patient sample. These re-
sults suggest that clonal dynamics are
not stochastic but are largely determined
by the genetic makeup of the clones that
likely reflects functional differences in
phenotypes. The results of the PDX clonal
evolution experiments were replicated
in different strains of immunodeficientElsevier Inc.mice, highlighting the dominant role of
cancer cell genotypes in this process.
PDX models have already been shown
to predict therapeutic responses in pa-
tients (Ellis et al., 2012). Nevertheless,
the question of whether the clonal dy-
namics observed in PDX models repro-
duce the clonal evolution of the patient’s
original cancer still remains. Answering
this would require the detailed analyses
of primary patient tumors transplanted
and passaged in animals in parallel with
the assessment of sequential biopsies of
the residual patient tumor and emerging
metastatic lesions. Although the pre-
dicted answer is that there will be signifi-
cant differences between the evolution
of PDX and patient tumors, the other
question is howmuch of these differences
influence the predictive value of preclini-
cal therapeutic studies and how we can
improve this by changing the way we
establish xenografts. Understanding the
genetic, epigenetic, and phenotypic het-
erogeneity of cancer cells is crucial for
the design of more effective cancer thera-
pies. However, since the microenviron-
ment of xenografts is drastically different
from that in the patient and the initial
engraftment selects for only a subset of
cancer cells, there is still a lot of room
for improvement in the way we derive
and propagate PDX tumors.
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